- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01045304
Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer
Multicenter, Randomized, Open Label Study Evaluating a Poly(ADP-ribose) Polymerase-1(PARP-1) Inhibitor, SAR240550 (BSI-201), Administered Twice Weekly or Weekly, in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer (mTNBC)
Primary Objective:
- To assess the objective response rate (ORR) of iniparib (SAR240550) administered as a 60min intravenous (IV) infusion twice weekly or weekly, in combination with gemcitabine/carboplatin chemotherapy regimen in patients with metastatic Triple Negative Breast Cancer (mTNBC).
Secondary Objectives:
- To assess the clinical benefit rate (CBR) defined as the rate of complete response (CR), partial response (PR) and stable disease (SD) lasting at least 24 weeks;
- To assess Progression-free survival (PFS) and the overall survival (OS);
- To assess the safety profile of each schedule of iniparib;
- To assess the biological activity in tumor tissue (substudy);
- To evaluate the pharmacokinetic (PK) profile of iniparib (substudy);
- To characterize molecular and biological profile of tumors (substudy);
- To assess the effect of iniparib on poly(ADP)-ribose (PAR) level in peripheral blood mononuclear cells (PBMC) (substudy).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The duration of the study for a patient includes a period for inclusion of up to 3 weeks. The patients may continue treatment until disease progression, unacceptable toxicity or consent withdrawal, followed by a minimum of 30-day follow-up after the last study treatment administration.
In case of discontinuation of study treatment, the patient will be considered as withdrawn from study treatment, and will be followed as planned for at least 30 days after the last administration of study treatment for safety purpose. In case of study treatment discontinuation without disease progression, efficacy data will be collected every 6 weeks until disease progression, death or end of study whatever comes first. After disease progression, the patient will be followed-up every 12 weeks (3 months) for overall survival until death or end of study.
The patients who benefit from the study treatment can continue until disease progression, toxicity or willingness to stop.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Parkville, Australia, 3052
- Sanofi-Aventis Investigational Site Number 036002
-
Perth, Australia, 6000
- Sanofi-Aventis Investigational Site Number 036001
-
Westmead, Australia, 2145
- Sanofi-Aventis Investigational Site Number 036003
-
-
-
-
-
Bruxelles, Belgium, 1000
- Sanofi-Aventis Investigational Site Number 056001
-
Leuven, Belgium, 3000
- Sanofi-Aventis Investigational Site Number 056002
-
-
-
-
-
Besancon Cedex, France, 25030
- Sanofi-Aventis Investigational Site Number 250005
-
Bordeaux, France, 33076
- Sanofi-Aventis Investigational Site Number 250003
-
Dijon, France, 21034
- Sanofi-Aventis Investigational Site Number 250002
-
Paris, France, 75970
- Sanofi-Aventis Investigational Site Number 250004
-
Paris Cedex 05, France, 75231
- Sanofi-Aventis Investigational Site Number 250006
-
Toulouse, France, 31052
- Sanofi-Aventis Investigational Site Number 250001
-
-
-
-
-
Genova, Italy, 16132
- Sanofi-Aventis Investigational Site Number 380004
-
Milano, Italy, 20133
- Sanofi-Aventis Investigational Site Number 380001
-
Modena, Italy, 41100
- Sanofi-Aventis Investigational Site Number 380002
-
Udine, Italy, 33100
- Sanofi-Aventis Investigational Site Number 380003
-
-
-
-
-
Rotterdam, Netherlands, 3075 EA
- Sanofi-Aventis Investigational Site Number 528001
-
-
-
-
-
Barcelona, Spain, 08035
- Sanofi-Aventis Investigational Site Number 724002
-
Madrid, Spain, 28050
- Sanofi-Aventis Investigational Site Number 724004
-
Málaga, Spain, 29010
- Sanofi-Aventis Investigational Site Number 724001
-
Valencia, Spain, 46010
- Sanofi-Aventis Investigational Site Number 724003
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Histologically documented breast cancer (either primary or metastatic site) that is ER (estrogen receptor)-negative, PgR (progesterone receptor)-negative ( <10% tumor staining by immunohistochemistry [IHC]) and HER2 (human epidermal growth factor 2) non-overexpressing by IHC (0,1+) or, IHC 2+ and FISH (fluorescence In situ hybridization) negative.
- Metastatic breast cancer with measurable disease by the revised guideline for Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1 criteria);
Prior treatment that includes:
- never having received anticancer therapy for metastatic disease OR
- having received 1 or 2 prior chemotherapy regimens in the metastatic setting (prior neo-adjuvant/adjuvant systemic therapy is considered as a prior chemotherapy if the first relapse occurred less than one year after the last treatment administration).
Exclusion criteria:
- Prior treatment with gemcitabine, carboplatin, cisplatin or any PARP inhibitor;
- Bone metastasis as only disease location (except for bone metastasis with measurable soft tissue component);
- Major medical conditions that might affect study participation e.g., uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection, cardiac disease.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gencitabine + iniparib twice weekly
Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles. Iniparib, 5.6 mg/kg IV over 60 minutes on Days 1, 4, 8 and 11 of 3-week cycles |
Pharmaceutical form: solution for infusion Route of administration: intravenous
Other Names:
Pharmaceutical form: solution for infusion Route of administration: intravenous Pharmaceutical form: solution for infusion Route of administration: intravenous |
Experimental: Gencitabine + iniparib weekly
Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles. Iniparib, 11.2 mg/kg IV over 60 minutes on Days 1 and 8 of 3-week cycles |
Pharmaceutical form: solution for infusion Route of administration: intravenous
Other Names:
Pharmaceutical form: solution for infusion Route of administration: intravenous Pharmaceutical form: solution for infusion Route of administration: intravenous |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR)
Time Frame: Up the cut-off date for analysis defined as 16 weeks after the 1st dose in the last participant (maximum follow-up of 14 months)
|
Proportion of participants with confirmed complete response (CR) or partial response (PR) as confirmed by an Independent Radiology Review Committee (IRRC) based on central review of scans in a blinded manner.
|
Up the cut-off date for analysis defined as 16 weeks after the 1st dose in the last participant (maximum follow-up of 14 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical benefit rate (CBR)
Time Frame: Up the cut-off date for analysis defined as 16 weeks after the 1st dose in the last participant (maximum follow-up of 14 months)
|
Proportion of participants with confirmed complete response (CR) or partial response (PR) ot stable disease (SD) greater than 24 weeks as confirmed by the IRRC.
|
Up the cut-off date for analysis defined as 16 weeks after the 1st dose in the last participant (maximum follow-up of 14 months)
|
Progression-free survival
Time Frame: Up the cut-off date for analysis defined as 16 weeks after the 1st dose in the last participant (maximum follow-up of 14 months)
|
Number of days from the date of randomization to the date of disease progression (ie, radiological progression based on IRRC assessment) or the date of death (from any cause), whichever is earlier.
|
Up the cut-off date for analysis defined as 16 weeks after the 1st dose in the last participant (maximum follow-up of 14 months)
|
Overall survival
Time Frame: Up the cut-off date for analysis defined as 16 weeks after the 1st dose in the last participant (maximum follow-up of 14 months)
|
Up the cut-off date for analysis defined as 16 weeks after the 1st dose in the last participant (maximum follow-up of 14 months)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Poly(ADP-ribose) Polymerase Inhibitors
- Gemcitabine
- Carboplatin
- Iniparib
Other Study ID Numbers
- TCD11418
- 2009-016091-80 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer, Metastatic
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
Clinical Trials on Iniparib
-
SanofiNo longer available
-
Institut du Cancer de Montpellier - Val d'AurelleTerminated
-
SanofiUNC Lineberger Comprehensive Cancer CenterCompletedBrain Metastases | Estrogen Receptor Negative (ER-Negative) Breast Cancer | Progesterone Receptor Negative (PR-Negative) Breast Cancer | Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast CancerUnited States
-
SanofiSOLTI Breast Cancer Research GroupCompletedBreast Cancer FemaleSpain, France, Germany
-
SanofiCompleted
-
SanofiCompletedSquamous Cell Lung CancerCanada, Belgium, Spain, United States, France, Germany, Hungary, Israel, Italy, Luxembourg, Netherlands, Poland, Romania, United Kingdom
-
SanofiGynecologic Oncology GroupCompleted
-
SanofiBiPar SciencesCompleted
-
SanofiCompletedPrimary Peritoneal Cancer | Advanced Epithelial Ovarian CancerUnited States
-
SanofiCompletedAdvance Solid TumorsJapan